Efficacy of Epiduo and Treatment Adherence of Adolescent Patients With Inflammatory Acne

Efficacy of Epiduo and Adherence of Patients Between 12 to 20 Years Using This Drug First Time in the Monotherapy of Moderate Inflammatory Acne

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01220102

Acronym

TEENA

Enrollment

3113

Registered

2010-10-13

Start date

2010-05-31

Completion date

2010-11-30

Last updated

2016-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne

Keywords

acne, Epiduo, adapalene/ benzoyl peroxide

Brief summary

The purpose of this observational study is to assess the efficacy of Epiduo and patient adherence under daily clinical practice conditions in adults and adolescents (12 to 20 years) with moderate inflammatory acne using this drug first time in topical monotherapy.

Detailed description

The objective of this observational study is to assess the efficacy of Epiduo and patient adherence under daily clinical practice conditions in adults and adolescents (12 to 20 years) with moderate inflammatory acne using this drug first time in topical monotherapy. This non-interventional trial will include a larger population of teenaged acne patients in order to establish the practical contribution of a new mini-questionnaire to the evaluation of adherence for the physician in the daily clinical practice in general and in young adults topically treated with Epiduo in particular. In addition safety and local tolerability profile of Epiduo are to be assessed under marketed conditions.

Interventions

DRUG0.1% adapalene/ 2.5% benzoyl peroxide

topical application, once per day

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Years to 20 Years

Healthy volunteers

Inclusion criteria

* The patient has been diagnosed with moderate inflammatory acne * Topical monotherapy of acne with Epiduo is indicated, the decision about treating the patient with Epiduo has been made independently from this study * The patient is aged between 12 and 20 years

Exclusion criteria

* Pregnancy or breastfeeding * Hypersensitivity to the medication or any of the ingredients * Other contraindications mentioned in the Epiduo SPC

Design outcomes

Primary

Measure	Time frame	Description
Severity of acne	at baseline and after 12 weeks of treatment	efficacy is assessed by change in severity of acne according to the Leeds revised acne grading system

Secondary

Measure	Time frame	Description
local skin irritations	over 12 weeks	—
treatment adherence	at final examination after 12 weeks of treatment	treatment adherence is assessed by the physician using a mini-questionnaire recently published by the international acne expert group Global Alliance to Improve Outcomes in Acne

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026